↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

Overview of attention for article published in Clinical Pharmacology & Therapeutics, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
1 news outlet
twitter
6 tweeters

Citations

dimensions_citation
145 Dimensions

Readers on

mendeley
125 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
Published in
Clinical Pharmacology & Therapeutics, April 2017
DOI 10.1002/cpt.583
Pubmed ID
Authors

B Moriyama, A Owusu Obeng, J Barbarino, SR Penzak, SA Henning, SA Scott, JAG Agúndez, JR Wingard, HL McLeod, TE Klein, SJ Cross, KE Caudle, TJ Walsh

Abstract

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas, poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org). This article is protected by copyright. All rights reserved.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 125 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 21%
Student > Doctoral Student 15 12%
Student > Ph. D. Student 14 11%
Student > Master 11 9%
Student > Bachelor 10 8%
Other 22 18%
Unknown 27 22%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 39 31%
Medicine and Dentistry 23 18%
Biochemistry, Genetics and Molecular Biology 21 17%
Agricultural and Biological Sciences 2 2%
Immunology and Microbiology 2 2%
Other 8 6%
Unknown 30 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2020.
All research outputs
#2,747,596
of 17,864,600 outputs
Outputs from Clinical Pharmacology & Therapeutics
#559
of 3,700 outputs
Outputs of similar age
#72,577
of 396,373 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#7
of 44 outputs
Altmetric has tracked 17,864,600 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,700 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 396,373 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.